|Mr. Gerald E. Commissiong||CEO, Pres & Director||N/A||N/A||1983|
|Dr. John Wesley Commissiong||Chief Scientific Officer, Director & Member of Scientific Advisory Board||N/A||N/A||1945|
|Mr. Robert Lewis Harris||Compliance Officer & Director||N/A||N/A||1944|
|Dr. Elise Brownell||Sr. VP of Operations & Project Management||N/A||N/A||N/A|
|Aimee Boutcher||Director of Investor Relations||N/A||N/A||N/A|
|Dr. Ravi Kiron||Sr. VP of Bus. Devel.||N/A||N/A||1960|
|Dr. Paula T. Trzepacz||Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics||N/A||N/A||N/A|
|Dr. Brian E. Harvey||Chief Regulatory Advisor & Member of Board of Advisors||N/A||N/A||N/A|
|Dr. Richard Kagan M.D.||Chief Medical Advisor to Cutanogen Corp.||N/A||N/A||N/A|
|Dr. Owen Garrick||Corp. Advisor||N/A||N/A||N/A|
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
Amarantus BioScience Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.